This major event brought together leading experts in the field of portal hypertension, including several members of the FILFOIE network:
– Dr Aurélie PLESSIER, coordinator of the FILFOIE network
– Prof. Pierre-Emmanuel Rautou
– Prof. Laure Elkrief
– Prof. Christophe Bureau
#PortalHypertension
“Interventional radiologists should not just deliver TIPS – incorporating IR in the holistic management of cirrhosis can help outcomes and patient care.”
#InterventionalRadiology #TIPS #PortalHypertension #Cirrhosis
buff.ly/2Osox8W (Dan Zhao et al.)
Ascites: Causes, Symptoms, SAAG Interpretation, Diagnosis & Management
#Ascites #Cirrhosis #PortalHypertension #LiverDisease #SAAG #AskDrPlus
Treatment response to #Bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD
JHEP Reports
www.jhep-reports.eu/article/S258...
#Liver #Cirrhosis #PortalHypertension
A recent @meduniwien.ac.at study investigated #cirrhosis pts with variceal bleeding over two 🕐 🕕 🕘 decades:
✅ decreasing rebleeding🩸rates
✅ lower bleeding-related ☠️ mortality
in the more recent decade ☺️
📕 GIE Endoscopy
🔗 www.giejournal.org/article/S001...
🩸Next - WP6: Coagulation & Hemostasis Research
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
Today these two fellows rocked their VENIA DOCENDI
🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension
my personal highlights:
@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB
Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a
💡 Did you know?
ARTEMIS Clinical Case 3 investigates cardiovascular complications after TIPS placement, predicting cardiovascular events and evaluating overall survival and cirrhosis outcomes.
#LiverHealth #PortalHypertension #ARTEMISEU
Drs. @LorenzBALCAR of @meduniwien.ac.at & @MartaTONON identify a #cirrhosis population with #ascites at particular risk for shortterm #PortalHypertension complications
@jhepatology.bsky.social Reports: t.ly/iCvXY
Ascites #Grade3 + 🚨 MELD ≥12 or 🚨 Na ≤135
➡️ good candidates for #TIPS
The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
🇦🇹 Austrian GI/Liver Meeting 2025
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
🔬 New #EquationsForLife! @reibergerthomas.bsky.social's Group studies #PortalHypertension & uses #OhmsLaw to model blood flow. Their 2024 studies reveal gene expression patterns linked to PH & show it is a key risk factor for complicatoins in #MASLD.
🔎 tinyurl.com/CeMMRR2024-R...
🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness.
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!
Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp
💡 Big moments:
#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)
#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)
#Portalhypertension Fans ⬇️
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
More on #PortalHypertension:
💡 TIPS for hydropic decompensation improves short-term outcome: a case-control study
#poster WED-186 by Eduardo Cervantes-Alvarez (@medblab.bsky.social), presented clinical data on the role of #TIPS in managing hydropic #decompensation of liver #cirrhosis.
#EASL2025
🌐 MOTION Work Package 2 🌐
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
#liver #PortalHypertension #clinicaltrails #cACLD
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
Welcome @cemm-vienna.bsky.social @bsky.app !!
The #HEPEX Lab @meduniwien.ac.at is part of #CeMM and investigates molecular mechanisms of #Fibrogenesis and #PortalHypertension
Just out: MICROB-PREDICT members have contributed to the newly published EASL #ClinicalPracticeGuidelines (CPG) on #TIPS, a procedure to address complications of #cirrhosis patients suffering from #PortalHypertension
👉 www.journal-of-hepatology.eu/article/S016... (DOI: 10.1016/j.jhep.2025.01.029)
#PortalHypertension Fans !! #liver 👍
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
The #Vienna #Liver #StudyGroups #VLSG are already looking forward to @easlnews.bsky.social congress in #Amsterdam
@mathiasjachs.bsky.social @georg-semmler.bsky.social
and many more fellows will present data on
#viralhepatitis and #portalhypertension
@bavenocoop.bsky.social
#LiverX #AustrianGI/Liver Society
Hepatologischer Frühling #Graz
🐘 #MASLD #MASH #Cirrhosis broad entity of pts with differing disease drivers
🎯 #Combined non-invasive tests #NITs for #Fibrosis & #PortalHypertension will enrich #atrisk population in #clinicaltrials
@natureportfolio.nature.com
📣 New article published in @drugsincontext.bsky.social
Is carvedilol superior to propranolol in patients with #cirrhosis with #portalhypertension: a systematic and meta-analysis
Rajpurohit et al.
#gastroenterology #hepatology #pharmacology
www.drugsincontext.com/is-carvedilo...
1/6 🚨 Modified direct intrahepatic portocaval shunt (DIPS) successfully controlled variceal bleeding in patients with severe portal vein occlusion (PVO) and cirrhosis!
Check out the latest study published in CVIR 👇
#PortalHypertension #InterventionalRadiology #DIPS
Great pHTN session at #TLM2024 ➡️ statin, AC, & anti-fibrotics are promising
➡️ carvedilol for all
➡️ preemptive #TIPS is life-saving with NNT 4️⃣‼️
#TLM2024 #liversky #portalhypertension
@atoosarabiee.bsky.social
